Understanding how AMPylation affects protein aggregation in neurodegenerative diseases
Elucidating the impact of FIC-1/FICD-mediated AMPylation on polyglutamine aggregation dynamics and toxicity
This study is looking at how a special change to proteins might help us understand and find new ways to treat Huntington's disease and spinocerebellar ataxia type 3, using tiny worms to see how these changes affect protein behavior.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10884449 on NIH RePORTER |
What this research studies
This research investigates the role of AMPylation, a specific protein modification, in the aggregation of proteins associated with Huntington's disease and spinocerebellar ataxia type 3. By studying the effects of this modification on protein dynamics, the research aims to uncover potential therapeutic targets that could mitigate the toxic effects of misfolded proteins. The approach involves using model organisms like C. elegans to explore the underlying mechanisms of these diseases and how AMPylation influences protein behavior. Patients may benefit from insights gained that could lead to new treatment strategies for these debilitating conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington's disease or spinocerebellar ataxia type 3.
Not a fit: Patients with other neurodegenerative diseases not related to polyglutamine expansion may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating Huntington's disease and spinocerebellar ataxia type 3.
How similar studies have performed: While the specific approach of targeting AMPylation in these diseases is relatively novel, similar research has shown promise in understanding protein aggregation dynamics in other neurodegenerative conditions.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Van Pelt, Kate Matthys — University of Michigan at Ann Arbor
- Study coordinator: Van Pelt, Kate Matthys
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.